324 related articles for article (PubMed ID: 9399220)
1. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Soykan I; Sarosiek I; Shifflett J; Wooten GF; McCallum RW
Mov Disord; 1997 Nov; 12(6):952-7. PubMed ID: 9399220
[TBL] [Abstract][Full Text] [Related]
2. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis.
Soykan I; Sarosiek I; McCallum RW
Am J Gastroenterol; 1997 Jun; 92(6):976-80. PubMed ID: 9177513
[TBL] [Abstract][Full Text] [Related]
3. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
4. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
5. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Mizuno Y; Kondo T; Takubo H; Yokochi F
No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
7. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment.
Koch KL; Stern RM; Stewart WR; Vasey MW
Am J Gastroenterol; 1989 Sep; 84(9):1069-75. PubMed ID: 2773901
[TBL] [Abstract][Full Text] [Related]
8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
9. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term.
Fiorucci S; Distrutti E; Gerli R; Morelli A
Am J Gastroenterol; 1994 Apr; 89(4):550-5. PubMed ID: 8147358
[TBL] [Abstract][Full Text] [Related]
10. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
11. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
[TBL] [Abstract][Full Text] [Related]
13. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
14. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Mizuno Y; Kondo T; Takubo H; Yokochi F
No To Shinkei; 1994 May; 46(5):465-71. PubMed ID: 8060685
[TBL] [Abstract][Full Text] [Related]
15. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
16. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
18. [Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease].
Nomoto M; Nakatsuka A; Nagai M; Yabe H; Moritoyo T; Moritoyo H; Nisikawa N
Rinsho Shinkeigaku; 2005 Nov; 45(11):895-8. PubMed ID: 16447756
[TBL] [Abstract][Full Text] [Related]
19. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Hauser RA; Holford NH
Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
Grimes JD; Delgado MR
Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
